What You Should Know:
– Ryght AI, an AI clinical trial developer, today announced a partnership with Biorasi, a global clinical research organization (CRO) specializing in dermatology, oncology, neurology, and nephrology studies.
– The collaboration will bring advanced, AI-driven feasibility capabilities to biotech and biopharma sponsors.
Redefine Clinical Trial Feasibility with AI Digital Twin Technology
Ryght AI is reshaping clinical research through a next-generation platform that creates dynamic AI digital twins of research sites worldwide. This innovation empowers sponsors and CROs to accelerate study startup with faster site selection, streamlined feasibility workflows, and advanced generative and agentic AI capabilities. The SOC Type 2-compliant platform enables seamless, real-time communication among sponsors, CROs, and sites, improving operational efficiency and reducing startup delays.
Biorasi’s Feasibility Team will immediately leverage Ryght AI’s platform for granular, real-time insights on site performance and recruitment metrics—critical for improving cost efficiency, de-risking trial startup, and avoiding recruitment bottlenecks.
“Traditional feasibility models are often limited by static, self-reported data,” said Chris O’Brien, CEO at Biorasi. “Ryght AI’s continuously updated digital twins and AI-driven automation allow us to generate recruitment forecasts based on real-world, site-specific data.”
As a member of the Ryght Research Network, Biorasi gains access to advanced AI tools, collaboration opportunities with leading institutions, and resources to develop solutions that broaden trial access and drive innovation. The network processes site-specific and industry-wide data to deliver real-time insights, optimize site selection, and automate workflows including feasibility assessment, patient pre-screening, and compliance monitoring—streamlining communication and accelerating patient selection.
Proprietary Platform Capabilities
Ryght AI’s suite of proprietary tools is designed to shorten timelines and enhance site selection accuracy:
· AI-powered digital twins of global clinical sites, continuously updated with recruitment capacity, trial history, and operational readiness
· Automated feasibility forms pre-filled with validated data, reducing timelines to under three weeks
· Agentic AI copilots for protocol parsing and rapid document generation, streamlining IRB packets, questionnaires, and investigator outreach
Therapeutic Area Applications
Biorasi will deploy Ryght AI’s platform across multiple specialties:
· Dermatology – Speeds startup in high-volume outpatient settings with variable enrollment rates by geography and indication
· Oncology – Partnerships with leading cancer centers (e.g., Emory Winship, USC Keck) enable rapid access to vetted, high-performance sites, improving feasibility in complex oncology trials
· Neurology – Real-time updates on site capacity reduce screen failure rates and improve rare disease recruitment forecasts
· Nephrology – Predictive analytics identify sites with proven operational performance and eligible patient pools for kidney-related studies
For sponsors, these capabilities translate into more accurate enrollment forecasts, refined budget modeling, faster site startup, and targeted engagement with high-capacity, high-fit partners—reducing the risk of costly delays or mid-trial setbacks.
